EXEL
Exelixis, Inc.
Biotechnology · Healthcare · United States
66.20
close · 2026-10-29
value
47
cheaper than peers47
quality
90
stronger fundamentals90
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 6.73× | 67 |
| forward P/E | 15.49× | 59 |
| EV to EBITDA | 15.44× | 49 |
| price to book | 8.94× | 23 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 44.4% | 93 |
| operating margin | 39.5% | 93 |
| debt to equity | 9.0% | 64 |
| revenue growth | 10.6% | 41 |
4 of 4 measures available
Facts
| market cap | $16B |
| free cash flow | $739.7M |
| employees | 1,077 |
| first trade | 2000-04-17 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.78 | 1.76 | 0.65 | 0.56 |
| free cash flow | $844.3M | $633.8M | $170.4M | $224.2M |
| net income | $782.6M | $521.3M | $207.8M | $182.3M |
| revenue | $2.32B | $2.17B | $1.83B | $1.61B |
| unusual items | -$20.5M | -$85.3M | $0 | $0 |